We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
4d Pharma Plc | LSE:DDDD | London | Ordinary Share | GB00BJL5BR07 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 16.36 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
20/8/2022 16:10 | I'm not a insolvency practitioner so I rely on their food for thought Donald! ...I can't post the link but have a look at webpage companydebt.com/comp | one_frankel | |
20/8/2022 15:26 | I know and that is why stating 'Minimum of a year on Average' is factually incorrect. A little knowledge is a dangerous thing | the donald | |
20/8/2022 11:48 | 'Minimum of a year on Average' which doesn't mean most are concluded within a few months Donald! | one_frankel | |
20/8/2022 10:05 | New update on MRx 0006 | the donald | |
17/8/2022 10:46 | Donald, If you went a little back in time to comment Re: 30080 then hopefully it should all finally be making some sense unless one has a slight inadequacy of understanding the comments of others! | one_frankel | |
16/8/2022 21:47 | One_Frankel16 Aug '22 - 14:02 - 30083 of 30090 0 1 0 On 'Average' Donald and 4D has quite a few strands to unravel through in its rather convoluted business structure wouldn't you say! Read your OWN post. You use the mis-spelt word minimum.'it takes a minium of a year on average for administration' .....your words, not mine | the donald | |
16/8/2022 21:41 | The FCA have a duty to fully investigate what's gone with DDDD pharmaceuticals....F | amaretto1 | |
16/8/2022 21:36 | The Neil Woodford connection of the past needs to be looked at here. Is their any connection to Steven O or Oxford finance ....Make the administrators aware of this angle ....Hargreaves Lansdown at the time were also implicated. Who ever is going down the legal route on here or LSE raise this point ! | amaretto1 | |
16/8/2022 19:00 | I think the company has played it inch perfect Cornetto (unfortunately not for those that bought much higher before the concerted demise) and I reckon that was always the company's intention to fully capitalise on closing that gap at around 83p with an incoming killer RNS but lets hope its exactly that! ...I'm not a huge fan of trials as you well now by now buddy but AGL has such a huge market not only in the US but worldwide to accomodate and theres certainly no obstacles or even excuses for it to achieve that now! ...Decent company I think, hehe! | one_frankel | |
16/8/2022 18:49 | Not that i know of anything coming from it ! | amaretto1 | |
16/8/2022 18:48 | Agree with that ... I'm considering.. update in a few weeks AGL yes well timed ... News on more than one front expected near term. Ovarian trial results..The big one imo will be a collaboration or some thing more ... with Abbot... who have been in Guildford lately i hear ! | amaretto1 | |
16/8/2022 18:14 | I'm not currently holding buddy but I think they've just been rather unfortuate with situations beyond their control but theres a serious lack of any communication from the BoD which isnt helping matters and could also be exacerbating the demise. ...Good result on Angle today, I timed it rather well! | one_frankel | |
16/8/2022 17:55 | What are your thoughts on ENET now frank ... seriously ! | amaretto1 | |
16/8/2022 14:43 | Is it possible for existing shareholders to form a consortium to buy the company. Investing a bit more may be the least worst case for us. If nothing else it could drive up the sell price. | buyhiselllo joe | |
16/8/2022 14:02 | On 'Average' Donald and 4D has quite a few strands to unravel through in its rather convoluted business structure wouldn't you say! ...And why would administrators expedite through the whole bloody process when they're actually in the business of profiting from it! | one_frankel | |
16/8/2022 11:52 | The question is when did the Co. breach the terms and when they ought to have notified the market about the same. Suppression if such information, if that is the case, would have caused investors to hang on to their shares when, if they had relevant information, they likely would have acted differently. | yasx | |
16/8/2022 11:03 | The Donald, The problem is the Board never really had a solution even when listed, so the idea that they may now have a proposal to get this out of administration is very fanciful indeed. You can't blame the Administrator for racking up costs - all this is down to Peyton. He essentially took out a loan for (net) 6M, agreed to give up all the Co. had if he failed to stick to the terms, one of which required him to raise sufficient cash by April. He did not. Entering into that loan was, at best, reckless. Given the amount, he could instead have scaled back some expenditure on non-core initiatives. But, even more reckless was the fact that not until after April did he and that numpty finance sidekick decide to take steps to start raising funds, by which time the markets had turned and everyone knew that given the loan agreement he was out of options. Now you have the administrator having already racked up fees of not far shy of 1M, all the projects essentially on hold and the Co. in the hands of another party once any sale is agreed, for so I assume. All this because of a loan of net 6M, astonishing given Peyton had spent considerable sums on the Co given to him by investors over the years. He has no relationships in finance, nor did he plan or think about anything. Either that, or this was deliberate destruction, and I don't think it was. | yasx | |
16/8/2022 07:29 | Minimum of a year for an administration. Absolute rubbish. I know quite a few insolvency professionals. Some wrap these up in a few weeks. Time is money... | the donald | |
16/8/2022 07:25 | GSK deal today ! | amaretto1 | |
16/8/2022 07:19 | Podium4 Aug '22 - 21:26 - 7718 of 7720 0 6 0 We shall wait and see backbone. From appearances Oxford did not act in good faith, and neither did the BoD. Whether the Administrators are also acting in good faith with regards a sale remains to be seen. Pathway Advisory are a relatively new outfit, a breakaway team from KMPG. They are first class in ability and reputation. 4D are very lucky such good quality insolvency professionals are running this process. I met one of them at the AGM. He came over very well. Direct and clear in terms of his objectives. Advised also will work with the BoD which is key imo to find the best possible solution, refinance or sale. | the donald | |
16/8/2022 06:17 | "We also charge £650 per man hour until we suck every last penny out of you" | katsy | |
15/8/2022 20:35 | DDDD Administrator's Proposals - "we commenced a sale of business process shortly after appointment. We have contacted nearly fifty large pharmaceutical businesses and smaller biotechnology companies (including other prominent players in the microbiome space). Due to the commercial sensitivity of this sales process, we can only provide limited narrative as to the exact progress to date. Offer deadlines have been set with all interested parties and the details of indicative offers received cannot be disclosed subject to confidentiality agreement provisions. Alongside the above sale of business activity, we continue to explore the possibility of a refinance of the Group and an exit from administration. Similarly to above, progress here is confidential and updates will be made available to creditors at the appropriate time | thiopia | |
15/8/2022 11:30 | Donald, its standard protocol for administrators to be working on more than one option and it takes a minium of a year on average for administration to conclude but there's certainly no harm with having some added optimism! | one_frankel |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions